162
Participants
Start Date
August 17, 2020
Primary Completion Date
July 31, 2024
Study Completion Date
January 1, 2025
Lu-PSMA
"Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles."
Enzalutamide
160 mg (four 40 mg capsules) daily.
St Vincents Hospital, Darlinghurst
Chris O'Brien Lifehouse, Camperdown
Northern Cancer Institute, Sydney
Macquarie University Hospital, Macquarie Park
Liverpool Hospital, Liverpool
St George Hospital, Kogarah
Calvary Mater Newcastle, Newcastle
Peter MacCallum Cancer Centre, Melbourne
The Alfred Hospital, Melbourne
Austin Health, Heidelberg
Monash Health, Clayton
Royal Brisbane and Women's Hospital, Brisbane
Royal Adelaide Hospital, Adelaide
Sir Charles Gairdner Hospital, Nedlands
Fiona Stanley Hospital, Perth
Collaborators (2)
National Health and Medical Research Council, Clinical Trials Centre
UNKNOWN
Prostate Cancer Research Alliance
UNKNOWN
Endocyte
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OTHER